Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of F182112 in Combination With Isatuximab and Lenalidomide in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Exploratory Clinical Study

NCT07828522 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT07828522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07828522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of F182112 in Combination With Isatuximab and Lenalidomide in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Exploratory Clinical Study
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
December 30, 2028
Enrollment
10 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma (mm), transplant-eligible patients